Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma

LESSONS LEARNED. Due to evolving imaging criteria in brain tumors and variation in magnetic resonance imaging evaluation, it is not ideal to use response rate as a primary objective. Future studies involving antiangiogenic agents should use overall survival. Disease‐expected toxicities should be con...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncologist
Hauptverfasser: Affronti, Mary Lou, Jackman, Jennifer Gamboa, McSherry, Frances, Herndon, James E., Massey, Elwood C., Lipp, Eric, Desjardins, Annick, Friedman, Henry S., Vlahovic, Gordana, Vredenburgh, James, Peters, Katherine B.
Format: Artigo
Sprache:Inglês
Veröffentlicht: AlphaMed Press 2018
Schlagworte:
Clinical Trial Results
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6156179/
https://ncbi.nlm.nih.gov/pubmed/29666296
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0149
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge